Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. ENLIE Pharmaceutical JSC's pretax income for the
six
months ended in Dec. 2019 was ₫-412 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2019 was ₫-2,600 Mil.
ENLIE Pharmaceutical JSC's pretax margin was -1.41%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENLIE Pharmaceutical JSC Pre-Tax Income Related Terms
ENLIE Pharmaceutical JSC Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ENLIE Pharmaceutical JSC's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENLIE Pharmaceutical JSC Pre-Tax Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ENLIE Pharmaceutical JSC's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where ENLIE Pharmaceutical JSC's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2019 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₫-2,600 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENLIE Pharmaceutical JSC (HSTC:BCP) has a Pre-Tax Income of ₫-2,600 Mil as of Dec. 2019. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on ENLIE Pharmaceutical JSC and its competitors.
Is ENLIE Pharmaceutical JSC's Pre-Tax Income too high?
ENLIE Pharmaceutical JSC's current Pre-Tax Income is ₫-2,600 Mil. Overall, ENLIE Pharmaceutical JSC has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENLIE Pharmaceutical JSC's Pre-Tax Income compare to ?
ENLIE Pharmaceutical JSC's Pre-Tax Income of ₫-2,600 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on ENLIE Pharmaceutical JSC and its competitors. ENLIE Pharmaceutical JSC's current Pre-Tax Income is ₫-2,600 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENLIE Pharmaceutical JSC stock overvalued right now?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a current Pre-Tax Income of ₫-2,600 Mil. The current Pre-Tax Income is ₫-2,600 Mil. ENLIE Pharmaceutical JSC's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For ENLIE Pharmaceutical JSC (HSTC:BCP), the current Pre-Tax Income is ₫-2,600 Mil as of Dec. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENLIE Pharmaceutical JSC is engaged in the production and trading of pharmaceuticals, medical supplies, cosmetics, foods, and functional foods. It is also engaged in the wholesale of other installation materials and equipment in the construction.
25GF Score
Get the complete analysis for HSTC:BCP
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:BCP has been successfully added to your 
